Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.12530/38420| Title: | Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. | |
| Authors: | ||
| Issue Date: | 2018 | |
| Citation: | AIDS.2018 02;(32)4:477-485 | |
| Abstract: | Bone mineral density (BMD) loss, a risk factor for osteoporosis, has been attributed to HIV infection and antiretroviral therapy (ART), including regimens containing tenofovir disoproxil fumarate. | |
| PMID: | 29239893 | |
| URI: | https://hdl.handle.net/20.500.12530/38420 | |
| Rights: | openAccess | |
| Appears in Collections: | Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos Hospitales > H. U. La Paz > Artículos | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| PMC5802259.pdf | 327.06 kB | Adobe PDF |  View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.